Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

Delaware's highest court ruled on Thursday that nearly 75,000 patients suing four large drugmakers cannot introduce reports ...